Prognostic Factors and Biomarker Performance in Patients with Colorectal Cancer Receiving Reduced-Dose 5-Fluorouracil Therapy: A Retrospective Cohort Analysis
Mei-Wen Chen, Jing-Jim Ou, Cheng-Shyong Chang · 2025
Read Prognostic Factors and Biomarker Performance in Patients with Colorectal Cancer Receiving Reduced-Dose 5-Fluorouracil Therapy: A Retrospective Cohort Analysis by Mei-Wen Chen, Jing-Jim Ou, Cheng-Shyong Chang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12786588.txt.
Description
Mei-Wen Chen, Jing-Jim Ou, and Cheng-Shyong Chang hunted prognostic markers in colon cancer patients on reduced drug doses in a 2025 paper. Many patients cannot tolerate full-dose 5-fluorouracil, and how blood markers forecast their course was unclear. The team reviewed 95 such patients treated at a central Taiwan medical center between 2017 and 2023.
Smoking, advanced stage, poor tumor differentiation, and high pretreatment CEA each predicted death on their own. In combined analysis, differentiation and CEA stayed independent predictors. The authors assembled the markers into a nomogram for individualized risk estimates. They argue that marker combinations, not single tests, should guide gentler dosing decisions in this vulnerable group.
Catalog record
| CREATOR | Mei-Wen Chen, Jing-Jim Ou, Cheng-Shyong Chang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |